Author

M. Franchini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Bosshart· 1 shared A. Casadevall· 1 shared A. Cornelius· 1 shared A. Lehmann· 1 shared A. Neculcea· 1 shared A. Ruiz· 1 shared A. Schlegel· 1 shared A. Zuercher· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Bosshart

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single cell lineage tracing reveals subclonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.

S. Pellecchia, M. Franchini, G. Viscido, R. Arnese, G. Gambardella

The paper uses single-cell lineage tracing and deep learning to study anti-EGFR therapy resistance in TNBC, identifying IGFBP2 as a driver of resistance and predicting afatinib sensitivity.

bioRxiv · Apr 4, 2023Cancer Biology

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB.1

D. J. Sullivan, M. Franchini, J. Senefeld, M. Joyner, A. Casadevall, D. Focosi

The paper shows that plasma from individuals who received booster vaccinations or recent Omicron infections neutralizes BQ.1.1 and XBB.1 variants more effectively than naive vaccinated individuals.

bioRxiv · Nov 25, 2022Microbiology

Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors

A. Ruiz, S. Benucci, U. Duthaler, C. P. Bachmann, M. Franchini, F. Noreen, L. Pietrangelo, F. Protasi, S. Treves, F. Zorzato

This study treats a mouse model of congenital myopathy with HDAC and DNA methyltransferase inhibitors, improving muscle strength and RyR1 protein content.

bioRxiv · Nov 9, 2021Physiology

Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates

M. Walser, S. Rothenberger, D. L. Hurdiss, A. Schlegel, V. Calabro, S. Fontaine, D. Villemagne, M. Paladino, T. Hospodarsch, A. Neculcea, A. Cornelius, P. Schildknecht, M. Matzner, M. Haenggi, M. Franchini, , Stittela

This paper develops potent anti-SARS-CoV-2 DARPin therapeutics with low picomolar neutralization efficacy and reports their protective efficacy in a hamster model.

bioRxiv · Aug 25, 2020 · PreprintImmunology